Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  OTC Bulletin Board - Other OTC  >  Easton Pharmaceuticals Inc    EAPH

EASTON PHARMACEUTICALS INC

(EAPH)
My previous session
Most popular
SummaryQuotesChartsNewsCompany 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Easton Announces Status Updates on its $2,600,000 Framing Contract to Construct 150 Homes, Including New Additional Project

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/11/2019 | 03:51pm EDT

TORONTO, ON, Jan. 11, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Easton Pharmaceuticals Inc. (OTC: EAPH) provides operational update on its $2,600,000 CDN framing contract to build approximately 150 homes just outside of Toronto, Ontario including possible new project.

Easton recently announced that it has entered into a $2,600,000 CDN framing contract and has commenced work on the framing of approximately 150 homes with a well-known prominent regional builder.

Easton can disclose that it has collected approximately $150,000 CDN in payments over the past 30 day period since operations commenced. Easton’s Director, Vince Demasi, who is also the operational manager for the project, stated that the good weather conditions up to now and the well-organized crew, have resulted in no delays with our building operations. Since the framing is ahead of schedule and all 30 full time employees being very productive and allowing East, has been presented with another possible building contract to construct up to 200 residential units in Welland, Ontario, Canada.

Additional details are expected to be made available in the next few weeks on a possible lucrative $30,000,000 building project in addition to its recently announced Cobourg, Ontario development project to build 42 residential units over the next 3 years, with the first phase approved and ready for 6 units in an existing mansion.

Easton is currently in the process of completing and filing its September 31, 2018 quarterly financial Statements and its December 31, 2018 year-end financial Statements following which, it will initiate an audit through auditors the Company has selected.       

About Easton Pharmaceuticals

Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries. The Company previously developed and owned an FDA-approved wound-healing medical drug and currently owns topically delivered drugs to treat cancer and other therapeutic products to treat various conditions that are all in various stages of development and approval. Easton, together with BMV Medica S.A. own the exclusive distribution rights in Mexico and Latin America for two patented women's diagnostic products and a novel natural treatment for Bacterial Vaginosis, which they have sub-licensed to Bayer and Gedeon Richter. In addition, a generic cancer drugs line is being developed for sale in Mexico. The company's gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of other drugs. As part of its strategic growth plan, the Company will be entering new lucrative market segments globally, including Gaming, Real Estate and Hospitality, among others.

For More Information on Easton and Affiliated and Partner Company's Visit:

http://www.eastonpharmaceuticalsinc.com

http://finance.yahoo.com/q?s=eaph

https://twitter.com/eastonpharma

Safe Harbor

This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when certain words or phrases such as "hope", "positive", "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.

CONTACT INFORMATION:
Evan Karras / CEO / President 
Tel: 647.362.5700  
Email: eastonpharma@protonmail.com

Easton Logo.png


© GlobeNewswire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EASTON PHARMACEUTICALS INC
03/05Easton Signs Agreement to Acquire Commercial Bakery with Projected Revenues O..
GL
02/05EASTON PHARMACEUTICALS : Announces Updates on Its $2,600,000 Framing Contract to..
AQ
02/05Easton Announces Updates on Its $2,600,000 Framing Contract to Construct 150 ..
GL
01/23Easton Announces Completion of Financial Statements With $200,000 in Sales in..
GL
01/12EASTON PHARMACEUTICALS : Announces Status Updates on its $2,600,000 Framing Cont..
AQ
01/11Easton Announces Status Updates on its $2,600,000 Framing Contract to Constru..
GL
01/03EASTON PHARMACEUTICALS : Announces Signing and Commencement of $2,600,000 Framin..
AQ
01/02Easton Pharmaceuticals Announces Signing and Commencement of $2,600,000 Frami..
GL
2018Easton Pharmaceuticals Completes Purchase of Development Project with Total P..
GL
2018Easton Pharmaceuticals Provides Company Update Including Hotel Acquisition in..
GL
More news
Chart EASTON PHARMACEUTICALS INC
Duration : Period :
Easton Pharmaceuticals Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Managers
NameTitle
Evan Karras President, Chief Executive Officer & Director
Vince Demasi Chief Operating Officer & Director
Jose Tiran Saucedo Chief Medical Officer
John Guerra Secretary & Director
Robert Vivacque Director
Sector and Competitors
1st jan.Capitalization (M$)
EASTON PHARMACEUTICALS INC39.53%0
GILEAD SCIENCES1.98%81 365
VERTEX PHARMACEUTICALS9.55%47 003
REGENERON PHARMACEUTICALS5.76%42 410
GENMAB7.54%10 705
SAREPTA THERAPEUTICS INC8.97%8 762